News
Archives
- 2017
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2016
- Oct (1)
- Apr (2)
- Jan (1)
- 2015
- 2014
- 2013
- Oct (1)
- Jul (1)
-
Apr (5)
- First investigator meeting for our new North Asia sites for the first time
- The National Cancer Institute (U.S) has recently labelled Aspirin in Colorectal Cancer as one of the most provocative questions in cancer
- We congratulate Dr Tham and team, and team from Sixth Affiliated Hospital
- Zhejiang and Zhongshan hospitals obtained IRB approval
- PIK3CA subgroup analysis included as a new secondary endpoint
- Jan (2)
- 2012
- Oct (2)
- Apr (1)
- Jan (1)
- 2011
- Oct (1)
- Jul (1)
- Apr (1)
1 Oct 2013
ASCOLT trial has achieved its highest monthly recruitment rate this quarter
ASCOLT trial has achieved its highest monthly recruitment rate this quarter.
The 2nd Affiliated Hospital of Zhejiang University and Zhongshan City People’s Hospital were kicked off this August and have both entered their first patients into study.
Ethics approval at Beijing University Cancer Hospital and Sun Yat Sen Cancer Centre Guangzhou
As we speak, our study protocol is also undergoing review at the National Cancer Institute Sri Lanka, Guangyi Hospital in Guangzhou and Changhai Hospital in Shanghai.